Variable |
Group A
One Joint (N = 12) |
Group B
Two Joints (N = 16) |
Group C
Three or more Joints (N = 13) |
P value
Group A vs
Group B vs
Group C |
Female Gender (%) |
12 (100%) |
13 (81.3%) |
12 (92.3%) |
0.36 |
Mean age at diagnosis SLE, years (range) |
32.7 (5-58) |
23.9 (8-43) |
24.1 (14-36) |
0.34 |
Median duration SLE to diagnosis of AVN, years (range) |
11 (1-23) |
10 (1-40) |
13 (1-32) |
0.63 |
Mean length of follow-up from diagnosis of AVN, months (range) |
46.8 (0-220) |
54.2 (0-129) |
89.9 (0-228) |
0.11 |
Mucocutaneous, No. (%) |
7 (58.3%) |
11 (68.8%) |
9 (69.2%) |
0.84 |
Arthritis, No. (%) |
11 (91.7%) |
13 (81.3%) |
11 (84.6%) |
0.86 |
Nephritis, No. (%) |
7 (58.3%) |
11 (68.8%) |
9 (69.2%) |
0.84 |
CNS disease, No. (%) |
0 |
2 (12.5%) |
6 (46.2%) |
0.01 |
Hematologic, No. (%) |
2 (16.7%) |
9 (56.3%) |
7 (53.8%) |
0.08 |
SLICC/ACR damage index, median (range) |
4.5 (1-9) |
3 (2-8) |
4 (2-7) |
0.48 |